A mechanism to initiate emergency type 2 myelopoiesis
Summary
This Nature paper describes how type 2 inflammatory signals (notably IL-33 released during helminth infection) trigger a rapid, programmed shift in bone marrow progenitor fate that increases production of basophils and eosinophils (BEM lineages). The authors identify LMO4 as an IL-33–induced GATA2 co-factor that reallocates GATA transcription-factor binding from erythroid/megakaryocyte (Ery–Meg) chromatin to BEM-specific regulatory regions. Mechanistically, LMO4 binding to GATA2 displaces FOG1/LMO2 from the GATA2 ZnF1 interaction, causing epigenetic and transcriptional reprogramming of oligopotent EMPPs towards BEMP commitment and downstream myeloid output.
Key experimental evidence includes: mouse helminth infection and IL-33 administration causing increased bone marrow IL-33, elevated Lmo4 expression in EMPPs, and myeloid bias in colony assays; gain- and loss-of-function Lmo4 experiments (lentiviral overexpression, knockdown, and transplantation) that alter BEMP versus preMegE frequencies and peripheral cell output; ChIP–seq/ATAC–seq and footprinting showing GATA2 reallocation; and demonstration that a human-relevant GATA2 point mutation (G320D) that blocks LMO4 binding prevents LMO4-driven reprogramming and impairs parasite control. Human xenograft data show IL-33 also upregulates LMO4 in human EMPP-like cells, indicating conservation.
Key Points
- Helminth infection (H. polygyrus) and IL-33 increase IL-33 in bone marrow and induce EMPP myeloid bias, raising basophil and eosinophil output at the expense of erythroid cells.
- LMO4 is upregulated in EMPPs by IL-33 (NF-κB dependent) and is sufficient to instruct myeloid (BEM) fate when expressed in EMPPs or preMegEs.
- LMO4 binds GATA2 in a manner mutually exclusive with FOG1/LMO2, displacing FOG1 and causing GATA2 reallocation from preMegE chromatin to BEMP-specific regulatory regions.
- A GATA2(G320D) mutation that selectively blocks the LMO4–GATA2 interaction prevents LMO4-mediated reprogramming, reduces BEMP/BEM production and impairs parasite control in vivo.
- The IL-33 → LMO4 → GATA2 reallocation axis is conserved in human progenitors (xenograft and single-cell data), highlighting translational relevance for type 2 inflammation and allergy biology.
Context and relevance
Type 2 myeloid cells (basophils, eosinophils, mast cells) are central to anti-parasite immunity but also to allergic disease when dysregulated. The paper places LMO4 as a conserved molecular switch that converts a systemic alarmin signal (IL-33) into a targeted change in progenitor fate, producing a rapid, demand-adapted supply of type 2 effector cells. This links extrinsic inflammatory cues to intrinsic reconfiguration of transcription-factor complexes and chromatin accessibility — a neat example of how the haematopoietic system tailors output to physiological need. Clinically, the mechanism suggests potential ways to modulate eosinophilia/basophilia selectively (for allergy, asthma or parasitology) by targeting LMO4, the LMO4–GATA2 interface or upstream IL-33 signalling.
Author style
Punchy: the study delivers a clear mechanistic story — from an extracellular alarmin to a single co-factor (LMO4) that retools a master regulator (GATA2) and flips progenitor fate. If you care about transcription-factor biology or therapeutic targeting of type 2 inflammation, the molecular detail is very relevant.
Why should I read this?
Want a crisp molecular explanation for how allergy-type white cells are rapidly produced? This paper walks you from infection/alarmin to chromatin and back to organismal impact. It’s short on waffle and long on mechanism — good if you’re time-poor and want the actionable bits (IL-33 → LMO4 → GATA2 reallocation; GATA2(G320D) blocks it).